Prescribing and monitoring hemodialysis dose  by Lowrie, Edmund G.
262   Kidney International (2008) 74 
commentar y
greater capacity to generate adenosine tri-
phosphate by anaerobic glycolysis during 
impaired oxidative phosphorylation, as 
might occur after ischemia.7 This, together 
with other factors such as loss of epithelial 
polarity, high water and solute fluxes, and 
low metabolic reserve, might contribute to 
higher susceptibility of the PT to various 
stresses, including ischemia.3 In addition, 
responses of the DT to ischemic injury 
involve altered expression of a variety of 
genes that might modulate susceptibil-
ity of this segment to injury. For exam-
ple, the extracellular signal-regulated 
kinase (ERK)8 and the cAMP-responsive 
element-binding protein9 are activated in 
the DT only after ischemia/reperfusion 
injury and each has a prosurvival role in 
experimental models of oxidant stress. 
Interestingly, each of these genes has been 
identified in experiments examining the 
issue of ischemic preconditioning.10
This raises the question of how inhibi-
tion of an event in the distal nephron could 
influence survival of proximal tubule cells 
and improve renal function, as has been 
demonstrated before. One possibility is the 
production by the medullary thick ascend-
ing limb of paracrine growth factors that 
may contribute to the survival of adjacent 
PTs.3 A similar situation exists for collecting 
ducts coursing through this region of the 
kidney, which are a source of insulin-like 
growth factor-1. For example, the expres-
sion of these growth factors is lost during 
ischemia/reperfusion injury.3 Accordingly, 
the DT possesses important autocrine and 
paracrine factors that, through ‘cross-talk’ 
between those neighboring segments, 
could facilitate survival or regeneration 
of the tubular epithelium after ischemic 
or toxic insults. This scenario might make 
it clear why inhibition of apoptosis in the 
DT has a larger than expected impact on 
kidney function (Figure 1).
Unfortunately, studies to date, includ-
ing those of Ma and Devarajan,1 are not 
robust enough to examine these issues 
and yield only possible glimpses of their 
importance to the syndrome of acute kid-
ney injury. The delineation of the roles of 
segment-specific paracrine, juxtacrine, 
and even intracrine support of the neph-
ron as a whole will not be possible until 
the identified crucial role players, such as 
Daxx, are manipulated in vivo at the right 
site and at the right time. Identification of 
a key role player in segment-specific out-
come offers the hope of pursuing such a 
strategy in vivo, with obvious therapeutic 
implications. It may change the current 
experimental paradigm of focusing on 
how to limit necrosis in the PT to how to 
limit apoptosis in the DT.
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Prescribing and monitoring 
hemodialysis dose
Edmund G. Lowrie1
Small patients require higher Kt/V, the ratio of dialysis dose (the product 
of small-molecule clearance (K) and dialysis session length (t) to body 
water volume (V), than large patients. The errors implicit in Kt/V for 
judging hemodialysis dose are reviewed; methods for prescribing 
hemodialysis based on new technology are discussed; and thoughts 
about future development are suggested.
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In this issue of Kidney International, 
Spalding et al.1 suggest that small patients 
treated at a uniform Kt/V target of 1.2 
receive inadequate dialysis if toxicity is 
more a function of metabolic activity than 
of urea distribution volume. Singer and 
Morton2 have offered similar thoughts 
based on the allometric scaling law; met-
abolic activity is related to geometric size 
as a power function (that is, Y = aXb).
The 1.2 value is accepted for index-
ing Kt to V.3 The ranges of Kt indexed 
to body surface area (Kt/BSA) and to 
a power of weight (W0.67) estimated 
using that Kt/V target were substantial.1 
They were lower for small than for large 
patients, leading the authors to conclude 
that using Kt/V underestimates needed 
dialysis dose, given the assumption that 
necessary Kt is more a function of meta-
bolic activity than of geometric size.
That conclusion,1 and therefore that 
assumption, is supported by empirical 
data based on both urea kinetics-based 
estimates4 and direct measurements of Kt 
using ionic dialysance.5–7 Kt was a curvi-
linear function of BSA in those studies, 
however, and not a simple linear ratio as 
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suggested by Spalding et al.1 Indeed, the 
risk profile for Kt/BSA was irrational.5 
Nevertheless, the curvilinear relationship 
between survival, Kt, and body size 
showed that small patients required pro-
portionally greater Kt (thus higher Kt/V) 
than did large patients. The relationship 
between body size and life-sustaining 
dose was decidedly nonlinear,4–7 so it 
seems clear that metabolic activity is 
important.
Why did we believe that the relation-
ship between Kt and body size is a Kt/V? 
Sargent and Gotch described pharma-
cokinetic equations over 30 years ago, 
assuming that the blood concentrations 
of substances determined uremic toxicity.8 
Urea was a convenient marker for small 
molecules. The National Cooperative Dial-
ysis Study (NCDS),9 a prospective two-
by-two factorial trial funded in 1976, used 
those equations to control urea concentra-
tion. Blood urea nitrogen (BUN; a proxy 
for small molecule–directed therapy) and 
dialysis session length (Time; a proxy for 
removing larger molecules) were the fac-
tors. The study was stopped early, with only 
151 patients randomized, because adverse 
medical outcome was much higher in the 
high-BUN than in the low-BUN groups 
(odds ≈ 5.0). Outcome in the short-Time 
groups was worse than in the long-Time 
groups (odds ≈ 1.5), but the level of sig-
nificance was marginal (P = 0.06).
A secondary analysis of NCDS out-
come data10 used the intermediate urea 
kinetic parameter Kt/V as the predictor 
measure. Low-BUN patients had higher 
Kt (and therefore Kt/V) than high-BUN 
patients, as expected. Clinical outcome 
was favorably associated with increasing V 
(F. Gotch; Ralph K. Davies Medical Center, 
San Francisco, CA, USA; personal com-
munication), but the premises on which 
the equations are based were not reevalu-
ated to see whether they remained valid 
when used to predict outcome instead of 
urea concentration. Time was ignored.
Much work followed to evaluate the 
best mathematical models for predicting 
BUN that were used in a second trial, the 
Hemodialysis Study (HEMO).11 HEMO 
evaluated Kt/V (high versus standard) 
and membrane flux (high versus low). 
There was no overall outcome differ-
ence between the high and standard 
Kt/V groups or between the flux groups. 
Females, but not males, in the standard 
Kt/V groups had worse outcomes than in 
the high Kt/V groups, but the statistical 
finding was marginal.
Using Kt/V for outcome as HEMO did 
relies on the assumptions that (1) urea 
kinetics is a good marker for toxicity, (2) 
Time is not important as an independ-
ent parameter (it is combined in a single 
ratio), and (3) the mathematical assump-
tions used for predicting concentration 
are valid for predicting outcome. It also 
relies on the assumption that the relation-
ship between treatment exposure and 
body size is linear with a 0-intercept (for 
example, Kt = 0 + 1.2 × V).
As it turns out, the knowledge base has 
changed since HEMO was designed. Eloot 
and colleagues have shown that the kinetic 
behaviors of other small molecules are 
quite different from those of urea.12 So the 
assumption that urea kinetics reflects the 
behaviors of other small molecules is incor-
rect. Furthermore, recent studies suggest 
that Time may well be an independent asso-
ciate of outcome;13,14 longer Time is asso-
ciated with better outcome. Disregarding 
Time on the basis of that marginal P-value 
of 0.06 may well have been an overly aggres-
sive interpretation of NCDS data.
Finally, the work of Spalding et al.1 and 
others2,4–7 indicates that the Kt versus 
body size relationship defining adequate 
treatment is not linear. V is not a simple 
diluent for urea when clinical outcome is 
considered. Body size is now recognized 
as a powerful predictor of outcome, as 
Spalding et al.1 suggest and many others 
have found.
The Kt/V ratio, therefore, divides one 
measure favorably associated with sur-
vival by another. Figure 1 illustrates the 
problem, and no one has argued effectively 
that such a practice is mathematically, 
scientifically, or logically sound. One can 
achieve target Kt/V values of, say, 1.2 by 
delivering suboptimal Kt to small patients. 
Those small patients then suffer the dual 
risk burdens of inadequate Kt and small 
body size. The kinetic ratio Kt/V is appro-
priate for predicting urea concentration 
but not for predicting clinical outcome.
The most recent Kidney Disease Out-
comes Quality Initiative (KDOQI) 
guidelines for hemodialysis3 tacitly 
acknowledge this fact. They retreat from 
two-pool kinetic models for Kt/V, used, for 
example, by HEMO,11 to a simpler single-
pool model. More to the point, they say 
women and small patients require higher 
Kt/V than the standard recommendation 
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figure 1 | Structural problems resulting from dividing one measure favorably associated 
with survival by another. A target Kt/V of 1.2, for example, is achieved by delivery of an 
inadequate Kt to small patients. Similarly, an adequate Kt delivered to small or malnourished 
patients gives the appearance of very good treatment (Kt/V = 1.7 here), while patients remain at 
substantial risk due to small body size. A high Kt delivered to large patients, however, is associated 
with good outcome even though the Kt/V appears inadequate. (Risk profiles were recast from 
Figure 11 in ref. 16.)
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(Clinical Practice Recommendations 4.5 
and 4.6).3 A constant ratio Kt/V, therefore, 
cannot be considered a reliable measure 
for hemodialysis dose if small patients 
require greater Kt/V per body size than 
large patients.
Fortunately, new ionic dialysance tech-
nologies measure Kt directly during each 
treatment. Fresenius Medical Care mar-
kets the online clearance monitoring 
(OCM) technology; the Diascan technol-
ogy is available from Gambro. The two 
technologies yield comparable Kt val-
ues.15 Diascan-measured values are about 
4% lower than those measured by OCM. 
There was also about a 6% difference due 
to the machine mechanics with which the 
technologies are installed. Methods for 
converting measurements from one device 
to values for the other are suggested.15
An empirical, nonlinear method relat-
ing outcome to Kt and body size (as BSA), 
based on OCM technology, has been 
described6 and validated.7 An appropriate 
Kt is selected from a table, or simple equa-
tion, for a patient’s BSA. It is then easily 
monitored during each treatment. Further 
work by others can refine those proposals 
and/or apply them to other technologies. 
In the meantime, however, Kt can now be 
prescribed and monitored easily without 
a need for formal mathematical models 
or complicated equations to estimate an 
uncertain V and/or a Kt/V.
Commentaries like this one often 
conclude with recommendations for 
further work. Four issues deserve brief 
mention. The first revisits earlier com-
ments about the influence of Time. We 
considered primarily Kt here, but K and 
Time (including frequency) should be 
evaluated separately in analytical mod-
els to see whether the parameters have 
separate effects as suggested by NCDS. 
Time and K, for example, can be evalu-
ated in factorial arrangements adjusting 
for body size.
The second and third issues con-
sider therapy factors other than 
small-molecule clearance. Enhanced 
removal of larger molecular species may 
contribute to patient well-being. The 
designs of both NCDS9 and HEMO11 
were based in part on such thoughts. 
Similarly, better methods for prescribing 
and judging water removal deserve scru-
tiny. Time might be important to both 
considerations.
Finally, how can new knowledge be 
integrated quickly into a bureaucratized 
clinical-care system such as that in 
which we find ourselves today? Current 
hemodialysis guidelines,3 for example, 
were two years in the making, restating 
similar guidelines drafted six years ear-
lier that simply restated even earlier 
guidelines (all Kt/V recommendations 
= 1.2). Federal and state bureaucracies in 
the United States oversee, pay, and regu-
late dialysis facilities. They set their own 
standards and have authority to deny 
payment and close facilities that do not 
comply. Hence, facilities and physicians 
understandably hesitate to use care pro-
cesses that do not conform to their over-
seers’ standards, even if those standards 
are outdated or scientifically suspect. No 
one can reasonably argue that the stand-
ard setting, oversight, and payment proc-
esses are efficient and bias free.
How, for example, does one change 
clinical practice using new knowledge 
showing that Kt/V leads to under-dial-
ysis? All regulatory and oversight agen-
cies require a Kt/V (or urea reduction 
ratio, a related measure)! Bureaucratized 
systems that centrally regulate care proc-
ess at the base (clinics) can thus stultify 
and frustrate progress. This thought may 
seem tangential to the main thrust of 
this Commentary. But it is not. Of what 
use are clinical advances such as these if 
they cannot be readily used to improve 
care quality?
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